Good2Go2 Corp.

(A Capital Pool Corporation)

Unaudited Condensed Interim Financial Statements

For the Three and Nine Months Ended

May 31, 2020

(Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

The accompanying unaudited condensed interim financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these interim financial statements in accordance with standards established by the CPA Canada for a review of interim financial statements by an entity's auditor.

GOOD2GO2 CORP.

Statements of Financial Position
Unaudited Condensed Interim Statements of Financial Position

		As at May 31, 2020		As at August 31, 2019
Assets				
Current assets				
Cash held in trust	$	245,986	$	124,091
Deferred offering costs		361		12,500
Total current assets		246,347		136,591
Total Assets	**$**	**246,347**	**$**	**136,591**
Liabilities and Shareholders' Equity				
Current liabilities				
Accounts payable and accrued liabilities	$	2,188	$	31,190
Total current liabilities		2,188		31,190
Shareholders' equity				
Common shares (Note 4 a)		321,149		150,000
Common share purchase warrants (Note 4 b)		11,871		
Common share purchase options (Note c)		37,641		
Deficit		(126,502)		(44,599)
Total shareholders' equity		244,159		105,401
Total Liabilities and Shareholders' Equity	**$**	**246,347**	**$**	**136,591**

Subsequent Event (Note 6)

The accompanying notes are an integral part of these financial statements

Approved by the Board of Directors

(signed) *"James Cassina"*
James Cassina, Director

(signed) *"Sandra Hall"*
Sandra Hall, Director

Good2Go2 Corp.

Unaudited Condensed Interim Statements of Loss and Comprehensive Loss

	Three Months Ended May 31, 2020	Nine Months Ended May 31, 2020	For the period from the Date of Incorporation (March 21, 2019) to May 31, 2019
Expenses			
Professional fees	$ -	$ 23,708	$ 6,500
Filing fees	12	9,061	8,193
Stock based compensation (Note 4 c)	-	37,641	-
Stock exchange fees	1,311	10,013	8,475
Transfer agent fees	973	1,480	
Net loss and comprehensive loss	**$ 2,296**	**$ 81,903**	**$ 23,168**
Net loss per share, basic and diluted	**$ 0.00**	**$ 0.09**	**$ 0.00**
Weighted Average shares outstanding, basic and diluted	**2,250,000**	**886,861**	**-**

The accompanying notes are an integral part of these financial statements

Good2Go2 Corp.

Unaudited Condensed Interim Statement of Changes in Shareholders' Equity

	SHARE CAPITAL Number of Common Shares	SHARE CAPITAL Common shares $	COMMON SHARE PURCHASE WARRANTS $	COMMON SHARE PURCHASE OPTIONS $	DEFICIT $	TOTAL SHAREOLDERS' EQUITY $
Balance, March 21, 2019	-	-	-	-	-	-
Share subscriptions (Note 4 a)	3,000,000	150,000	-	-	-	150,000
Net loss for the period	-	-	-	-	(23,168)	(23,168)
Balance, May 31, 2019	3,000,000	150,000	-	-	(23,168)	126,832
Net loss for the period	-	-	-	-	(21,431)	(21,431)
Balance, August 31, 2019	3,000,000	150,000	-	-	(44,599)	105,401
Share subscription (Note 4 a)	200,000	10,000	-	-	-	10,000
Initial public offering (Note 4 a)	2,250,000	225,000	-	-	-	225,000
Fair value of agent warrants (Note 4 b)	-	(11,871)	11,871	-	-	-
Offering costs	-	(51,980)	-	-	-	(51,980)
Stock based compensation (Note 4 c)	-	-	-	37,641	-	37,641
Net loss for the period	-	-	-	-	(81,903)	(81,903)
Balance, May 31, 2020	**5,450,000**	**321,149**	**11,871**	**37,641**	**(126,502)**	**244,159**

The accompanying notes are an integral part of these financial statements

GOOD2GO2 CORP.

Unaudited Condensed Interim Statement of Cash Flows

	Nine Months Ended May 31, 2020	For the period from the Date of Incorporation (March 21, 2019) to May 31, 2019
Cash (used in) provided by		
Operating activities		
Net loss for the period	$ (81,903)	$ (23,168)
Item not involving cash:		
Stock based compensation	37,641	-
Working capital adjustments:		
Decrease (increase) in deferred offering costs	12,139	(12,500)
(Decrease) increase in accounts payable	(29,002)	14,190
Net cash used in operating activities	(61,125)	(21,478)
Financing activities		
Share subscription (Note 4 a)	10,000	150,000
Initial public offering (Note 4 a)	225,000	-
Offering costs	(51,980)	-
Net cash provided by financing activities	183,020	150,000
Increase in cash for the period	121,895	128,522
Cash, beginning of period	124,091	-
Cash, end of period	**$ 245,986**	**$ 128,522**

The accompanying notes are an integral part of these financial statements

1. INCORPORATION AND NATURE OF OPERATIONS

Good2Go2 Corp. was incorporated under the *Canada Business Corporations Act* on March 21, 2019 and registered in the Province of Ontario on March 21, 2019 ("Good2Go2" or the "Company"). As the Company was incorporated on March 21, 2019, the comparative figures presented herein are for the period from the date of incorporation March 21, 2019 to May 31, 2019. The Company is classified as a Capital Pool Corporation, as defined in Policy 2.4 of the TSX Venture Exchange (the "Exchange"). The principal business of the Company will be the identification and evaluation of assets or businesses with a view to completing a Qualifying Transaction ("QT"). The Company has not commenced operations and has no assets other than cash held in trust. The Company's continuing operations as intended are dependent upon its ability to identify, evaluate and negotiate an acquisition, or business, or an interest therein. Such an acquisition will be subject to the approval of the regulatory authorities concerned and, in the case of a non- arm's length transaction, of the majority of the minority shareholders.

The proceeds raised from the issuance of share capital may only be used to identify and evaluate assets or businesses for future investment, with the exception that not more than the lesser of 30% of the gross proceeds realized by the Company, in respect of the sale of its securities, or $210,000, may be used for purposes other than evaluating businesses or assets. These restrictions apply until completion of a QT by the Company, as defined under the policies of the Exchange. The Company is required to complete its QT on or before two years from the date the Company receives regulatory approval.

The Company's head office and registered office is located at 1 King Street West, Suite 1505, Toronto, Ontario, M5H 1A1. The Company's common shares trade on the TSX Venture Exchange under the symbol GOAL.P.

2. BASIS OF PREPARATION

Statement of Compliance
These unaudited interim condensed financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretation Committee ("IFRIC"). These unaudited interim condensed financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by the IASB and interpretations issued by IFRIC. On July 6, 2020, the Board of Directors of the Company approved the unaudited interim condensed financial statements for the three and nine month period ended May 31, 2020.

Basis of Measurement
The Financial Statements have been prepared on a historical cost basis except for certain financial instruments measured at fair value.

Functional and Presentation Currency
The functional and presentation currency of the Company is Canadian dollars.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Share Capital
Common shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognized as a deduction from equity.

Basic and Diluted Loss Per Share
Basic loss per share is computed by dividing the net loss applicable to common shares by the weighted average number of common shares outstanding for the relevant period, excluding shares held in escrow.

Diluted loss per share is calculated by dividing the net loss applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding if potentially dilutive instruments were converted. 3,200,000 common shares were excluded from the calculation as they were contingently issuable and all conditions necessary for their issuance have not been satisfied (Note 4 a).

Offering Costs
Offering costs relate to expenditures incurred in connection with the Company's share offerings and are charged against share capital.

Share-based Compensation
Equity-settled share based payments for directors, officers, employees, and consultants are measured at fair value at the date of grant and recorded as compensation expense in the financial statements. Share options are measured at the fair value of each tranche on the grant date and are recognized in their respective vesting period using the Company's expected forfeiture rate. Any consideration paid by directors, officers, employees and consultants on exercise of equity-settled share based payments is credited to share capital. Shares are issued from treasury upon the exercise of equity-settled share-based instruments.

Financial Instruments
Recognition
The Company recognizes financial assets and financial liabilities on the date the Company becomes a party to the contractual provisions of the instruments.

Classification
The Company classifies its financial assets and financial liabilities in the following measurement categories: i) those to be measured subsequently at fair value (either through other comprehensive loss or through profit or loss), and ii) those to be measured at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as those to be measured subsequently at fair value through profit or loss (irrevocable election at the time of recognition). For assets and liabilities measured at fair value, gains and losses are either recorded in profit or loss or other comprehensive loss.

The Company reclassifies financial assets when and only when its business model for managing those assets changes. Financial liabilities are not reclassified.

The Company has implemented the following classifications:

Cash held in trust is classified as fair value through profit and loss and any period change in fair value is recorded in profit or loss. Accounts payable and accrued liabilities are classified as other financial liabilities and measured at amortized cost using the effective interest rate method.

Measurement
All financial instruments are required to be measured at fair value on initial recognition, plus, in case of a financial asset or financial liability not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issue of the financial asset or financial liability. Transaction costs of financial assets and financial liabilities carried at FVTPL are expensed in profit or loss.

Financial assets that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments or principal and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with any changes taken through profit and loss or other comprehensive loss (irrevocable election at the time of recognition).

Additional fair value measurement disclosure includes classification of financial instrument fair values in a fair value hierarchy comprising three levels reflecting the significance of the inputs used in making the measurements which are as follows:

Level 1: Valuations based on quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2: Valuations based on directly or indirectly observable inputs in active markets for similar assets or liabilities, other than Level 1 prices, such as quoted interest or currency exchange rates; and

Level 3: Valuations based on significant inputs that are not derived from observable market data, such as discounted cash flow methodologies based on internal cash flow forecasts.

Cash held in trust is a level 1 financial instrument measured at fair value on the statements of financial position.

Income Taxes
Income tax expense consists of current and deferred tax expense. Current and deferred tax are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or other comprehensive income.

Current tax is recognized and measured at the amount expected to be recovered from or payable to the taxation authorities based on the income tax rates enacted or substantively enacted at the end of the reporting period and includes any adjustment to taxes payable in respect of previous years.

Deferred tax is recognized on any temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax baes used in the computation of taxable earnings. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized and the liability is settled. The effect of a change in the enacted or substantively enacted tax rates is recognized in net earnings and comprehensive income or in equity depending on the item to which the adjustments relate.

Deferred tax assets are recognized to the extent future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the assets to be recovered.

Measurement Uncertainty
The preparation of financial statements, in conformity with IFRS accounting principles, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates used in the financial statements.

New Accounting Standards issued
IFRS 16, Leases (IFRS “16”). Issued in January 2016, IFRS 16 establishes principles for the recognition, measurement, presentation and disclosure of leases, with the objective of ensuring that lessees and lessors provide relevant information that faithfully represents those transactions. This standard introduces a single lessee accounting model and requires a lessee to recognize assets and liabilities for all leases with a term of more than twelve months, unless the underlying asset is of low value. A lessee is required to recognize a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. IFRS 16 applies to annual reporting periods beginning on or after January 1, 2019. As at May 31, 2020, the Company did not have any lease obligations.

4. SHARE CAPITAL

a) Common Shares

Authorized:
Unlimited common shares

Issued:
The following table sets out the changes in common shares during the period.

	Number of Common Shares	Amount $
Balance, March 21, 2019	-	-
Share subscriptions (1)	3,000,000	150,000
Balance, May 31, 2019 and August 31, 2019	3,000,000	150,000
Share subscription (1)	200,000	10,000
Initial public offering (2)	2,225,000	225,000
Fair value of agent warrants (2)	-	(11,871)
Offering costs (2)	-	(51,980)
Balance, May 31, 2020	**5,450,000**	**321,149**

1) Escrowed Shares
The Company issued a total of 3,200,000 common shares at $0.05 per share for total proceeds of $160,000. The 3,200,000 common shares issued at $0.05 per share, will be held in escrow pursuant to the requirements of the Exchange. All common shares granted to directors and officers prior to the completion of a Qualifying Transaction, must also be deposited in escrow until the final exchange bulletin is issued.

All common shares of the Company acquired in the secondary market prior to the completion of a Qualifying Transaction by a Control Person, as defined in the policies of the Exchange, are required to be deposited in escrow. Subject to certain permitted exemptions, all securities of the Company held by principals of the resulting issuer will also be subject to escrow.

2) Initial Public Offering
On February 13, 2020, the Company completed its initial public offering (the "Offering") of 2,250,000 common shares at a purchase price of $0.10 per common share for gross proceeds of $225,000. During the period ended May 31, 2020, the Company incurred costs of $51,980 directly related to the Offering.

Haywood Securities Inc., (the "Agent") acted as the agent for the initial public offering. In connection with the Offering, the Company granted to the Agent, common share purchase warrants to acquire 225,000 common shares (the "Warrants"). Each Warrant is exercisable to acquire one common share at a price of $0.10 until February 12, 2022. The estimated fair value attributed to the Warrants was $11,871. In connection with the Offering, the Agent was paid a cash commission equal to 10% of the aggregate gross proceeds from the sale of the common shares. The Company also paid a corporate finance fee of $12,500 to the Agent and reimbursed the Agent for legal fees and other reasonable expenses incurred pursuant to the Offering.

Weighted Average Shares Outstanding
The following table summarizes the weighted average shares outstanding:

	Three Months Ended May 31, 2020	Nine Months Ended May 31, 2020	From the date of Incorporation March 31, 2019 to May 31, 2019
Weighted Average Shares Outstanding, basic and diluted	2,250,000	886,861	-

As at May 31, 2020, 3,200,000 common shares were excluded from the calculation as they were contingently issuable and all conditions necessary for their issuance have not been satisfied. At May 31, 2020, there were 225,000 Warrants and 505,000 Options that could be exercised, however they are anti-dilutive.

The effects of any potential dilutive instruments on loss per share are anti-dilutive and therefore have been excluded from the calculation of diluted loss per share.

b) Common Share Purchase Warrants

The following table sets out the changes in warrants for the periods set out:

Warrants	Number of Warrants	Weighted Average Price $
Outstanding, March 21, 2019, May 31, 2019 and August 31, 2019	-	-
Warrants issued	225,000	0.10
Balance, May 31, 2020	**225,000**	**$0.10**

In connection with the Offering, the Company granted to the Agent warrants to acquire 225,000 common shares (the "Warrants"). Each Warrant is exercisable to acquire one common share at a price of $0.10 until February 12, 2022. The fair value of the Warrants were estimated on the date of the issue using the Black-Scholes option pricing model with the following assumptions: dividend yield 0%, discount rate 1.51%, expected volatility 100% and expected life of 2 years. The fair value attributed to the 225,000 Warrants was $11,871.

The following table summarizes the outstanding warrants as at May 31, 2020:

Number of Warrants	Exercise Price	Expiry Date	Weighted Average Remaining Life (Years)	Warrant Value ($)
225,000	$0.10	February 12, 2022	1.70	11,871

c) Common Share Purchase Options

The Company has a stock option plan to provide incentives for directors, officers, employees and consultants of the Company. Options may be granted for a maximum term of five years from the date of the grant. They are non-transferable and are exercisable as determined by the Directors when the option is granted. Options expire within 12 months after completion of a qualifying transaction or within 90 days of termination of employment or holding office as director or officer of the Company and, in the case of death, expire within a maximum period of one year after such death, subject to the expiry date of the option. The stock option plan is subject to regulatory approval. Any shares issued upon exercise of the options prior to the Company entering into a Qualifying Transaction will be subject to escrow restrictions.

Upon closing of the Offering, the Company granted 505,000 common share purchase options to directors and officers. Each common share purchase option entitles the holder to acquire one common share of the Company at an exercise price of $0.10 until February 12, 2025 (the "Options"). The fair value of the Options were estimated on the date of the issue using the Black-Scholes option pricing model with the following assumptions: dividend yield 0%, discount rate 1.39%, expected volatility 100%, forfeiture rate 0% and expected life of 5 years. The Company recorded the estimated fair value of the Options of $37,641 as non-cash stock-based compensation expense.

The following table is a summary of the status of the Company's stock options and changes during the periods set out:

	Number of Options	Weighted Average Exercise Price $
Balance, March 21, 2019, May 31, 2019 and August 31, 2019	-	-
Granted	505,000	0.10
Balance, May 31, 2020	**505,000**	**0.10**

The following table is a summary of the Company's stock options outstanding and exercisable as at May 31, 2020:

Options Outstanding				Options Exercisable	
Exercise Price	Number of Options	Weighted Average Remaining Life (Years)	Expiry Date	Number of Options	Weighted Average Exercise Price $
$0.10	505,000	4.71	February 12, 2025	505,000	0.10

Any shares issued upon exercise of the options prior to the Company entering into a Qualifying Transaction will be subject to escrow restrictions.

The stock option plan is subject to regulatory approval.

5. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Capital Management

The Company's objective when managing capital is to maintain its ability to continue as a going concern, in order to provide returns for the shareholders and benefits for other stakeholders. The Company includes equity, comprised of share capital and deficit, in the definition of capital.

The Company's primary objective, with respect to its capital management, is to ensure that it has sufficient cash resources to fund the identification and evaluation of potential acquisitions. To secure the additional capital necessary to pursue these plans, the Company may attempt to raise additional funds through the issuance of equity or by securing strategic partners.

The proceeds raised from the issuance of common shares may only be used to identify and evaluate assets or businesses for future investment, with the exception that not more than the lesser of 30% of the gross proceeds from the issuance of shares or $210,000 may be used to cover prescribed costs of issuing the common shares or administrative and general expenses of the Company. These restrictions apply until completion of a Qualifying Transaction by the Company as defined under the Exchange policy 2.4.

Risk Disclosures and Fair Values

The Company's financial instruments, consisting of cash held in trust and accrued liabilities, approximate fair value due to the relatively short-term maturities of the instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Covid-19

In March 2020, the World Health Organization declared a global pandemic related to the virus known as COVID-19. The expected impacts on global commerce are anticipated to be far reaching. To date there have been significant wide-spread stock market declines and the movement of people and goods has become restricted. As the Company has no material operating income or cash flows, it will be reliant on additional financing to fund ongoing operations and future acquisitions. An extended disruption may affect the Company's ability to obtain additional financing. The impact on the economy and the Company is not yet determinable; however, the Company's financial position, results of operations and cash flows in future periods may be materially affected. In particular, there may be heightened risk of liquidity or going concern uncertainty.

6. SUBSEQUENT EVENT

On June 29, 2020, the Company announced that it has entered into a letter of intent (the "LOI") effective June 24, 2020 as amended July 3, 2020, to complete a qualifying transaction (the "Acquisition") pursuant to which the Company will, directly or indirectly, acquire all of the issued and outstanding securities of Canadian Teleradiology Services, Inc. ("CTS"), an arm's length Canadian company whose principal business activity is providing teleradiology services (remote radiology) to smaller urban and rural hospitals, using licensed IT platforms and hosted servers.

For the purposes of the Acquisition, it is intended that the shareholders of CTS will receive 27,275,000 common shares (on a post-consolidated basis) of the Company (the "G2G2 Shares"), in exchange for 100% of their common shares of CTS (the "CTS Shares") at an exchange ratio to be determined, assuming completion of the Consolidation of the G2G2 Shares, and other securities of the Company, on the basis of one new share for every two old shares upon completion of the Acquisition (the "Consolidation");

In connection with the Acquisition, CTS intends to complete a brokered private placement financing of subscription receipts (the "Subscription Receipts") for aggregate gross proceeds of at least CAD$4,000,000 (the "Financing"). Mackie Research Capital will act as the agent in connection with the Financing to offer the Subscription Receipts for sale, on a commercially reasonable efforts and agency basis. It is expected that the proceeds of the Financing will be used for general corporate purposes.

Pursuant to the LOI, the Acquisition is subject to the parties successfully entering into a definitive business combination agreement in respect of the Acquisition, and a number of other conditions, including but not limited to: completion of customary due diligence, receipt of all necessary regulatory, corporate and third-party approvals, exchange approval, compliance with all applicable regulatory requirements, and all requisite board and shareholder approvals being obtained.